Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 21, 2015, 25 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,597.00 to $2,165,180.58.

Highlighted Stocks Traded by Insiders:

PetMed Express (PETS) - FREE Research Report

Rosenbloom Bruce S, who is Chief Financial Officer at PetMed Express, sold 2,167 shares at $15.40 on Jan. 21, 2015. Following this transaction, the Chief Financial Officer owned 46,517 shares meaning that the stake was reduced by 4.45% with the 2,167-share transaction.

The shares most recently traded at $16.23, up $0.83, or 5.11% since the insider transaction. Historical insider transactions for PetMed Express go as follows:

  • 4-Week # shares sold: 500
  • 12-Week # shares sold: 500
  • 24-Week # shares sold: 3,000

The average volume for PetMed Express has been 155,100 shares per day over the past 30 days. PetMed Express has a market cap of $318.1 million and is part of the health care sector and drugs industry. Shares are up 12.73% year-to-date as of the close of trading on Wednesday.

PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats. The stock currently has a dividend yield of 4.33%. The company has a P/E ratio of 18.5. Currently, there are no analysts who rate PetMed Express a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PETS - FREE

TheStreet Quant Ratings rates PetMed Express as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, increase in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full PetMed Express Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ares Capital Corporation (ARCC) - FREE Research Report

Bartlett Steve, who is Director at Ares Capital Corporation, bought 100 shares at $15.97 on Jan. 21, 2015. Following this transaction, the Director owned 3,900 shares meaning that the stake was boosted by 2.63% with the 100-share transaction.

The shares most recently traded at $15.92, down $0.05, or 0.31% since the insider transaction. Historical insider transactions for Ares Capital Corporation go as follows:

  • 4-Week # shares bought: 100
  • 12-Week # shares bought: 71,900
  • 24-Week # shares bought: 82,200

The average volume for Ares Capital Corporation has been 2.1 million shares per day over the past 30 days. Ares Capital Corporation has a market cap of $5.0 billion and is part of the financial sector and financial services industry. Shares are up 2.47% year-to-date as of the close of trading on Wednesday.

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. The stock currently has a dividend yield of 9.51%. The company has a P/E ratio of 8.3. Currently, there are 7 analysts who rate Ares Capital Corporation a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARCC - FREE

TheStreet Quant Ratings rates Ares Capital Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Ares Capital Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CenturyLink (CTL) - FREE Research Report

Melville C G Jr, who is Director at CenturyLink, sold 500 shares at $38.70 on Jan. 21, 2015. Following this transaction, the Director owned 7,995 shares meaning that the stake was reduced by 5.89% with the 500-share transaction.

The shares most recently traded at $38.80, up $0.10, or 0.26% since the insider transaction. Historical insider transactions for CenturyLink go as follows:

  • 4-Week # shares sold: 7,525
  • 12-Week # shares sold: 127,948
  • 24-Week # shares sold: 127,948

The average volume for CenturyLink has been 3.0 million shares per day over the past 30 days. CenturyLink has a market cap of $22.1 billion and is part of the technology sector and telecommunications industry. Shares are down 2.4% year-to-date as of the close of trading on Wednesday.

CenturyLink, Inc. operates as an integrated telecommunications company in the United States. The company operates through four segments: Consumer, Business, Wholesale, and Data Hosting. The stock currently has a dividend yield of 5.58%. The company has a P/E ratio of 27.5. Currently, there are 6 analysts who rate CenturyLink a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTL - FREE

TheStreet Quant Ratings rates CenturyLink as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, solid stock price performance, impressive record of earnings per share growth, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full CenturyLink Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null